Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
mixture
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03678350CT.gov Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Photofrin Ii (this asset) | Roswell Park Cancer Institute | P1 | CC · 47 |
| Cis-Diamminedichloroplatinum Ii | Dr Jean Yannis PERENTES | P2 | BB |
| Adriamycin | Mayo Clinic | P2 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | BB |
| Sargramostim | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Tamoxifen | Ottawa Regional Cancer Centre | P2 | B |
| L-Alanosine | Memorial Sloan Kettering Cancer Center | P2 | B |
| Alpha-Interferon | St. Vincent Medical Center - Los Angeles | P2 | B |
| 18f-fspg | Andrei Iagaru | P2 | B |
+42 more in the Malignant Mesothelioma cohort
Other indications for Photofrin Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1/2 | B · 63 |
| Central Nervous System Neoplasm | — | P3 | B · 62 |
| Extrahepatic Bile Duct Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Photofrin Ii in Malignant Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/photofrin-ii-malignant-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →